Last week, Merck entered into a non-exclusive license and option agreement with Cyprumed GmbH, aiming to enhance its peptide offerings through innovative oral delivery technology. Despite this collaboration, Merck's share price remained essentially flat over the week. This lack of movement occurred amidst a broader market sell-off led by the technology sector, due to new U.S. restrictions on chip exports to China. While Merck's agreements showcased a strong focus on growth and collaboration, these positive strides were likely countered by the negative sentiment in the market driven by trade tensions.

Merck has 1 warning sign we think you should know about.

We've found 25 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Merck's recent collaboration with Cyprumed GmbH, aimed at expanding its peptide offerings through oral delivery technology, is likely to influence its broader growth narrative focused on oncology and cardiometabolic sectors. Over the past five years, Merck has experienced an impressive total shareholder return of 22.00%. However, it's essential to note that Merck underperformed both the US market, which returned 5.9%, and the US Pharmaceuticals industry, which saw a decline over the past year.

The Cyprumed agreement, despite not affecting short-term share price movements, might still impact Merck's revenue and earnings forecasts positively, aligning with its strategic focus on pipeline development and product launches. The anticipated introduction of WINREVAIR and the continued success of KEYTRUDA could drive significant growth in revenue, offsetting short-term setbacks like the paused GARDASIL shipments in China.

While the current share price of US$78.95 remains below the analyst consensus price target of US$110.89, suggesting potential upside, investors should assess whether they agree with the analysts' assumptions, which include a projected 4.4% annual revenue growth and an increase in profit margins over the next few years. With the stock trading at a discount to its price target, the market may eventually respond to Merck's strategic efforts in these key therapeutic areas.

Examine Merck's earnings growth report to understand how analysts expect it to perform.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:MRK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com